|Mr. Jianjun Liu||Financial Director||N/A||N/A||1978|
|Ms. Su Mei Jiang||Exec. Deputy GM & Director||N/A||N/A||1965|
|Mr. Jie Ping Sun||Deputy GM & Director||N/A||N/A||1970|
|Mr. Hong Bin Dai||Deputy GM & Director||N/A||N/A||1976|
|Dr. Lian Shan Zhang Ph.D.||Deputy GM & Director||N/A||N/A||1962|
|Mr. Kai Hong Yuan||Deputy Gen. Mang.||N/A||N/A||1965|
|Mr. Ya Ping Shen||Deputy Gen. Mang.||N/A||N/A||1964|
|Mr. Xu Gen Sun||Deputy Gen. Mang.||N/A||N/A||1970|
|Mr. Wei Kang Tao||Deputy Gen. Mang.||N/A||N/A||1964|
|Mr. Cheng Liao||Deputy Gen. Mang.||N/A||N/A||1975|
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co., Ltd.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 2.